Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

Kim Linton, Graham P. Collins, Francesco Forconi, Nirav N. Shah, Karan Dixit, Talha Munir, Zulfa Omer, Dima El-Sharkawi, Jeanette Doorduijn, Alvaro Alencar, Pam Mckay, John Riches, Mary Gleeson, David Lewis, Allison Winter, Sarah Injac, Ted Shih, Srinand Nandakumar, May Tan, Ganesh CheralaErin Meredith, Alexey Danilov

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S360-S361
Number of pages2
JournalClinical Lymphoma, Myeloma and Leukemia
Volume24
Issue numberS1
Early online date26 Aug 2024
DOIs
Publication statusPublished - 1 Sept 2024
EventEuropean Hematology Association (EHA) Hybrid Congress 2024 - IFEMA MADRID RECINTO FERIAL (fairgrounds), Madrid, Spain
Duration: 13 Jun 202416 Jun 2024
https://ehaweb.org/congress/eha2024-hybrid-congress/eha2024-hybrid-congress-4/

Keywords

  • B-cell malignancies
  • BTK degrader
  • BTK mutations
  • Cll
  • Nx-5948
  • relapsed/refractory CLL

Cite this